Akari Therapeutics Plc (AKTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on November 26, 2025, regarding an event reported on November 24, 2025. The Company is a biopharmaceutical entity incorporated in England and Wales, with its principal executive offices in Tampa, Florida. Its American Depositary Shares (ADSs) trade on The Nasdaq Capital Market under the symbol "AKTX."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance.
Material Changes
On November 24, 2025, the Company received a Notification Letter from Nasdaq stating it is not in compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The deficiency exists because the closing bid price of the ADSs remained below $1.00 per share for 30 consecutive business days prior to the notification date.
Outlook, Management Commentary, and Risks
- Compliance Period: The Company has 180 calendar days, until May 25, 2026, to regain compliance. To do so, the ADSs must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
- Secondary Compliance Option: If the Company fails to regain compliance by May 25, 2026, it may be eligible for an additional 180-day period if it meets the market value of publicly held shares requirement and all other initial listing standards, excluding the bid price requirement.
- Delisting Risk: Failure to qualify for or meet the requirements of the second compliance period will result in a determination to delist the ADSs. The Company retains the right to appeal such a determination to a Hearings Panel.
- Management Action: The Company intends to monitor the closing bid price and may consider implementing a ratio change of its ADSs to regain compliance.
- Current Status: The Notification Letter has no immediate effect on the listing or trading of the ADSs, which will continue to trade on the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of AKTX ADSs to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding potential reverse stock splits or ADS ratio changes.
- Track the Company's progress toward the 10 consecutive business days of compliance required by May 25, 2026.
- Review the Company's market value of publicly held shares to determine eligibility for the second compliance period if the first is missed.